The purpose of this study is to compare the results of two different sleep tests in Alzheimer's patients with no symptoms or early symptoms. Participants will undergo two simultaneous sleep tests (polysomnography) in a sleep laboratory for two nights and one sleep test at home for three nights. For each participant, the study will last at least a week and will last up to three months.
Have mild cognitive impairment, subjective memory complaints, or normal cognition.
Evidence of the presence of Alzheimer's pathology as measured by amyloid positron emission tomography (PET), cerebrospinal fluid biomarkers (amyloid beta and tau), or blood biomarkers.
Montreal Cognitive Assessment (MoCA) score of 24 or greater.
Clinical Dementia Rating Scale (CDR) global score of 0 or 0.5.
Severe illness that in the investigator's judgement would adversely affect the participant's participation in the study.
Skin illness that may interfere with study assessments.
Has a pacemaker or implantable cardioverter defibrillator.
Diagnosed with a sleep disorder.
Singaporean age 55-85 with mild memory complaints or MCI who are otherwise healthy.
Cohort
Prospective
Mobile EEG
DeviceDevice measures electrical activity in the brain, pulse rate, blood oxygen saturation levels, changes in blood flow and volume, motion and snoring.
Activity Monitor
DeviceDevice monitors physical movement.
Sleep Study
DeviceIn-Laboratory overnight assessment using EEG, electromyography to measure muscle movement, eye movement, electrical activity in the heart, blood oxygen saturation levels and breathing levels.
Percentage of Agreement between Participants with the Same Results in Sleep Staging Using EEG and Sleep Study
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
